Articles producció científica> Medicina i Cirurgia

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study

  • Dades identificatives

    Identificador: imarina:9187231
    Handle: https://hdl.handle.net/20.500.11797/imarina9187231
    Autors:
    Castells, LluisRimola, AntoniManzardo, ChristianValdivieso, AndresLuis Montero, JoseBarcena, RafaelAbradelo, ManuelXiol, XavierAguilera, VictoriaSalcedo, MagdalenaRodriguez, ManuelBernal, CarmenSuarez, FranciscoAntela, AntonioOlivares, Sergiodel Campo, SantosLaguno, MontserratFernandez, Jose R.de la Rosa, GloriaAgueero, FernandoPerez, InakiGonzalez-Garcia, JuanEsteban-Mur, Juan I.Miro, Jose M.FIPSE LT-HIV Investigators
    Resum:
    Background & Aims: The aim of this study was to evaluate the results of treatment with pegylated interferon and ribavirin for the recurrence of hepatitis C after liver transplantation in HCV/ HIV-coinfected patients. Methods: This was a prospective, multicentre cohort study, including 78 HCV/HIV-coinfected liver transplant patients who received treatment for recurrent hepatitis C. For comparison, we included 176 matched HCV-monoinfected patients who underwent liver transplantation during the same period of time at the same centres and were treated for recurrent hepatitis C. Results: Antiviral therapy was discontinued prematurely in 56% and 39% (p = 0.016), mainly because of toxicity (22% and 11%, respectively; p = 0.034). Sustained virological response (SVR) was achieved in 21% of the coinfected patients and in 36% of monoinfected patients (p = 0.013). For genotype 1, SVR rates were 10% and 33% (p = 0.002), respectively; no significant differences were observed for the other genotypes. A multivariate analysis based on the whole series identified HIV-coinfection as an independent predictor of lack of SVR (OR, 0.17; 95% CI, 0.06-0.42). Other predictors of SVR were donor age, pretreatment HCV viral load, HCV genotype, and early virological response. SVR was associated with a significant improvement in survival: 5-year survival after antiviral treatment was 79% for HCV/HIV-coinfected patients with SVR vs. 43% for those without (p = 0.02) and 92% vs. 60% in HCV-monoinfected patients (p < 0.001), respectively. Conclusions: The response to pegylated interferon and ribavirin was poorer in HCV/HIV-coinfected liver recipients, particularly those with genotype 1. However, when SVR was achieved, survival of coinfected patients increased significantly. (C) 2014 European Association

  • Altres:

    Autor segons l'article: Castells, Lluis; Rimola, Antoni; Manzardo, Christian; Valdivieso, Andres; Luis Montero, Jose; Barcena, Rafael; Abradelo, Manuel; Xiol, Xavier; Aguilera, Victoria; Salcedo, Magdalena; Rodriguez, Manuel; Bernal, Carmen; Suarez, Francisco; Antela, Antonio; Olivares, Sergio; del Campo, Santos; Laguno, Montserrat; Fernandez, Jose R.; de la Rosa, Gloria; Agueero, Fernando; Perez, Inaki; Gonzalez-Garcia, Juan; Esteban-Mur, Juan I.; Miro, Jose M.;FIPSE LT-HIV Investigators
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Jorba Martin, Rosa Maria
    Paraules clau: Virological response Survival Ribavirin Recurrence of hepatitis c Recipients Pegylated-interferon Peginterferon Multicenter experience Liver transplantation Human-immunodeficiency-virus Hiv infection Hcv infection Hcv Efficacy Coinfection Antiviral treatment Antiviral therapy Antiretroviral therapy
    Resum: Background & Aims: The aim of this study was to evaluate the results of treatment with pegylated interferon and ribavirin for the recurrence of hepatitis C after liver transplantation in HCV/ HIV-coinfected patients. Methods: This was a prospective, multicentre cohort study, including 78 HCV/HIV-coinfected liver transplant patients who received treatment for recurrent hepatitis C. For comparison, we included 176 matched HCV-monoinfected patients who underwent liver transplantation during the same period of time at the same centres and were treated for recurrent hepatitis C. Results: Antiviral therapy was discontinued prematurely in 56% and 39% (p = 0.016), mainly because of toxicity (22% and 11%, respectively; p = 0.034). Sustained virological response (SVR) was achieved in 21% of the coinfected patients and in 36% of monoinfected patients (p = 0.013). For genotype 1, SVR rates were 10% and 33% (p = 0.002), respectively; no significant differences were observed for the other genotypes. A multivariate analysis based on the whole series identified HIV-coinfection as an independent predictor of lack of SVR (OR, 0.17; 95% CI, 0.06-0.42). Other predictors of SVR were donor age, pretreatment HCV viral load, HCV genotype, and early virological response. SVR was associated with a significant improvement in survival: 5-year survival after antiviral treatment was 79% for HCV/HIV-coinfected patients with SVR vs. 43% for those without (p = 0.02) and 92% vs. 60% in HCV-monoinfected patients (p < 0.001), respectively. Conclusions: The response to pegylated interferon and ribavirin was poorer in HCV/HIV-coinfected liver recipients, particularly those with genotype 1. However, when SVR was achieved, survival of coinfected patients increased significantly. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
    Àrees temàtiques: Química Medicina ii Medicina i Interdisciplinar Hepatology General medicine Gastroenterology & hepatology Engenharias iv Engenharias ii Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: rosamaria.jorba@urv.cat
    Identificador de l'autor: 0000-0003-3307-4340
    Data d'alta del registre: 2024-09-07
    Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
    Enllaç font original: https://www.journal-of-hepatology.eu/article/S0168-8278(14)00538-8/fulltext
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Journal Of Hepatology. 62 (1): 92-100
    Referència de l'ítem segons les normes APA: Castells, Lluis; Rimola, Antoni; Manzardo, Christian; Valdivieso, Andres; Luis Montero, Jose; Barcena, Rafael; Abradelo, Manuel; Xiol, Xavier; Aguiler (2015). Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study. Journal Of Hepatology, 62(1), 92-100. DOI: 10.1016/j.jhep.2014.07.034
    DOI de l'article: 10.1016/j.jhep.2014.07.034
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2015
    Tipus de publicació: Journal Publications

  • Paraules clau:

    Gastroenterology & Hepatology,Hepatology
    Virological response
    Survival
    Ribavirin
    Recurrence of hepatitis c
    Recipients
    Pegylated-interferon
    Peginterferon
    Multicenter experience
    Liver transplantation
    Human-immunodeficiency-virus
    Hiv infection
    Hcv infection
    Hcv
    Efficacy
    Coinfection
    Antiviral treatment
    Antiviral therapy
    Antiretroviral therapy
    Química
    Medicina ii
    Medicina i
    Interdisciplinar
    Hepatology
    General medicine
    Gastroenterology & hepatology
    Engenharias iv
    Engenharias ii
    Educação física
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología

  • Documents:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar